Polishing methods for monoclonal IgG purification

Process Scale Bioseparations for the Biopharmaceutical Industry

Volumn , Issue , 2006, Pages 491-505

  Gagnon, Pete ^a  

^a BIO RAD LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123403477     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (16)

1. Gagnon P, Purification Tools for Monoclonal Antibodies, Tucson, Validated Biosystems, 1996.
2. Curtis S, Lee K, Brorson K, and Xu Y, Generic/matrix evaluation of SV40 clearance by anion exchange in flow-through mode, Biotechnol. Bioeng., 2003, 84, 179-186.
3. Sjoquist J, Meloun B, and Hjelm H, Staphylococcus aureaus after digestion with lysostaphin, Eur. J. Biochem., 1972, 29, 572-578.
4. Diesenhofer J, Jones TA, Huber R, Sjodahl J, and Sjoquist J, Crystallization, crystal structure analysis and atomic model of the complex formed by a human Fc fragment and fragment B of protein A from Staphylococcus aureaus, Hoppe Seylar's Z. Physiol. Biochem., 1978, 359, 975-985.
5. Bloom J, Wong MF, and Mitra G, Detection and reduction of protein A contamination in immobilized protein A purified monoclonal antibody preparations, J. Immunol. Meth., 1989, 117, 83-89.
6. Weary M and Pearson F III, A manufacturer's guide to depyrogenation, BioPharm. Manuf., 1988, 1, 22-29.
7. Shadle PJ, Erickson JC, Scott RG, and Smith TM, Antibody Purification, U.S. Patent 5,429,746, 1995.
8. Gagnon P, Grund E, and Lindback T, Large scale process development for hydrophobicinteractionchromatography, Part1, Gelselectionanddevelopment of binding conditions, BioPharm, 1995, 8, 21-27.
9. Gagnon P and Grund E, 1996, Large scale process development for hydrophobic interaction chromatography, Part 3, Factors affecting capacity determination, BioPharm, 1996, 9, 34-39.
10. Mitoma S, Development of a New Toyopearl® Hydrophobic Interaction Chromatographic Resin for Protein Purification, 4th HIC/RPC Bioseparation Conference, Palm Harbor, FL, February 15-19, 2004.
11. Franklin S, Protein A removal from IgG on CHT Ceramic Hydroxyapatite support, Bio-Rad Technical note, 2849, 2004.
12. Josic D, Loster K, Kuhl R, Noll F, and Reusch J, Purification of monoclonal antibodies by hydroxyapatite HPLC and size exclusion HPLC, Hoppe Seylar's Z. Physiol. Biochem., 1991, 372, 149-156.
13. Franklin S, Removal of aggregate from an IgG4 product using CHT ceramic hydroxyapatite, Bio-Rad Technical note 2940, 2003.
14. Gagnon P, An enigma unmasked; how hydyroxyapatite works and how to make it work for you, http://www.validated.com/revalbio/pdffiles/hxyapt.pdf, (accessed July 1998).
15. U.S. Food and Drug Administration, Guidance for Industry, PAT - A framework for innovative pharmaceutical development, manufacturing, and quality assurance, http://www.fda.gov/cvm/guidance/published.html (accessed September 2004).
16. Gottschalk U, Downstream processing of monoclonal antibodies: from high dilution to high purity, BioPharm Int., 2005, 18, 42-58.